Skip to main content
. 2017 Jul 18;8(35):59148–59155. doi: 10.18632/oncotarget.19324

Table 2. Summary of meta-analysis results.

N Model Pooled OR (95% CI) P value Heterogeneity(P, I2) Publication bias Conclusion
Total 4 Random 15.61 (4.09-59.61) <0.001 0.086, 54.5% 0.308 Positive
Asian 2 Fixed 69.61 (14.05-344.93) <0.001 0.896, 0.0% 1.000 Positive
Non-Asian 2 Fixed 5.86 (2.11-16.24) 0.001 0.831, 0.0% 1.000 Positive
Prospective 3 Fixed 8.56 (3.36-21.78) <0.001 0.187, 40.3% 1.000 Positive
Retrospective 1 77.00 (8.53-694.81) <0.05 Positive
VF 3 Random 25.38 (4.31-149.65) <0.001 0.076, 61.2% 1.000 Positive
VA 1 5.10 (1.00-26.30) 0.034 Positive
Follow-up ≥ 3 months 3 Random 25.12 (3.88-162.67) 0.001 0.081, 60.2% 1.000 Positive
Follow-up < 3 months 1 6.40 (1.70-23.10) 0.007 Positive
Pituitary adenoma 2 Random 15.41 (1.35-175.70) 0.028 0.085, 66.2% 1.000 Positive
Other tumor types 2 Random 18.84 (1.68-211.09) 0.017 0.057, 72.5% 1.000 Positive
Transsphenoidal 2 Random 15.41 (1.35-175.70) 0.028 0.085, 66.2% 1.000 Positive
Transcranial/unknown 2 Random 18.84 (1.68-211.09) 0.017 0.057, 72.5% 1.000 Positive

VF visual field, VA visual acuity, N number of included studies, OR odds ratio, CI, confidence interval.